Navigation Links
Sanofi-aventis Delivers 2008 Results Above Guidance
Date:2/11/2009

with double-digit growth in all three regions: 15.9% in the United States, 10.8% in Europe, and 13.8% in the "Other Countries" region.

(3) Excluding net sales of Ambien IR(R) in the United States in Q1 2007 and Q1 2008, and of Eloxatin(R) in Europe in 2007 and 2008

Fourth-quarter net sales of the hypnotics Ambien CR(R) and Ambien IR(R) in the United States were $170 million and $24 million respectively. Over the full year, net sales of Ambien CR(R) totaled $681 million, and Ambien IR(R) posted net sales of $125 million. In Japan, Myslee(R), the leading hypnotic on the market, again performed well: net sales (consolidated by sanofi-aventis since January 1, 2008) increased by 17.8% (to EUR 49 million) in the fourth quarter and by 14.9% (to EUR 142 million) over the full year.

In the United States, net sales of Eloxatin(R), the leading cytotoxic agent in the colorectal cancer market as an adjuvant and in the metastatic phase, rose by 6.9% to EUR 265 million in the fourth quarter and by 6.2% to EUR 948 million over 2008 as a whole, driven by the adjuvant indication. In the "Other Countries" region, the product reported robust growth of 13.4% to EUR 186 million.

Net sales of Acomplia(R), which was withdrawn from the market in the fourth quarter, totaled EUR 72 million in 2008.

Worldwide presence(1) of Plavix(R) / Iscover(R)

    EUR million                         Change on a          Change on a
                                         comparable           comparable
                                Q4 2008     basis   FY 2008      basis
    Europe                        457        +1.8%   1,833        +3.2%
    United States                 978       +11.6%   3,351       +21.1%
    Other Countries               270       +19.5%     959       +22.0%
    TOTAL                       1,
'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
2. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
3. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
4. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
5. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
6. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
7. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
8. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
9. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
10. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
11. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected ... Stewart American Made Awards (MSAMAs), an annual competition in ... the fields of crafts, design, food and style. ... in the MSAMAs, which celebrates entrepreneurs and artisans who ... communities and changing the way we shop, work and ...
(Date:10/1/2014)... 2014 Nordic Naturals is kicking ... special cause. The campaign—“Buy One Bottle. Help Two ... Veterans, a nonprofit organization that helps rebuild the ... dogs that would otherwise face euthanasia. From October ... support monthly donations of Nordic Naturals omega-3s to ...
Breaking Medicine News(10 mins):Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... , , , SEATTLE, July 17 ... by exacerbating conditions like hypertension, stress and fatigue, but also by causing people ... , Physicians at The Polyclinic in Seattle are offering suggestions for ... health. , , Don, t put ...
... , WASHINGTON, July 17 The Association ... Director of Policy and Public Affairs, in response to the AMA,s endorsement ... American Medical Association has sold out patients and the profession by endorsing ... "Why did the AMA do it? For a few dollars increase ...
... , , , ... (Nasdaq: NGSX ) announced today that Bruce A. Peacock has ... on his responsibilities as CEO of privately-held Alba Therapeutics. , ... no opportune time to resign, I feel confident that NeurogesX is well ...
... and avoided vitamin B deficiency , FRIDAY, July ... gastric bypass surgery helps patients lose weight faster and ... Probiotics are the "good" bacteria found in yogurt and ... University School of Medicine study included 44 patients who ...
... , CAMBRIDGE, Mass., July 17 Biopure Corporation ... The Nasdaq Stock Market, by letter dated July 17, 2009, that its ... because of concerns raised by the Company,s filing for protection under Chapter ... of business on July 28, 2009. , , ...
... , Cabinet Secretaries Kathleen Sebelius, Hilda L. ... community forum and hold m edi ... WASHINGTON , July 17 U.S. Department of ... U.S. Department of Agriculture Secretary Tom Vilsack and U.S. Department of Veterans Affairs Secretary Eric ...
Cached Medicine News:Health News:How to Afford Health Care in Hard Times 2Health News:Doctors: AMA Has Sold Out Patients & the Profession For A Few Dollars 2Health News:NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors 2Health News:NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors 3Health News:NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors 4Health News:Top Obama administration officials to hold rural health community forum 2
(Date:9/30/2014)... 2014 This study provides an analysis ... solutions including nuclear imaging informatics, PET imaging informatics, ... assesses the size of the market based on ... projects future growth based on the current drivers ... place in the broader markets for imaging equipment, ...
(Date:9/30/2014)... -- Decision Resources Group finds that the Asia Pacific ... China , India , Japan ... 2023. Dental implant procedure volumes will grow as physicians are increasingly ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Puma Biotechnology, Inc., a development stage biopharmaceutical ... license the worldwide commercial rights to neratinib, a ... transduction through the epidermal growth factor receptors, ErbB1 ... is being studied in the neoadjuvant, adjuvant and ...
... Corp. (OTCQB: CYCA), leading the way to cost effective ... Erik Stephansen to President of its eHealth division.  Mr. ... part of the company,s recent launch of their CyttaConnect™ ... network and its partners, FDA approved Bluetooth medical devices. ...
Cached Medicine Technology:Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5New Leader for CyttaConnect™ Medical Monitoring eHealth Division 2New Leader for CyttaConnect™ Medical Monitoring eHealth Division 3